TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03167164

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Fully human anti-PD-L1 IgG1 lambda monoclonal antibody

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Recombinant human anti-VEGF IgG1 monoclonal antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 5'-deoxy-5-fluoro-N-\[(pentyloxy) carbonyl\]-cytidine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: (SP-4-2)-diamminedichloroplatinum(II)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 2-\[bis(2-chloroethyl)amino\]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil
Description: 5-fluoro-2,4 (1H,3H)-pyrimidinedione

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Calcium N-\[p-\[\[\[(6RS)-2-amino-5-formyl-5,6,7,8-tetrahydro-4-hydroxy-6-pteridinyl\]methyl\]amino\]benzoyl\]-L-glutamate (1:1)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-Paclitaxel
Description: 5β,20-Epoxy-1,2α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: omega-3-acid ethyl esters
Description: Omega-3-acid ethyl esters

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: radiation

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALT-803
Description: Recombinant human super agonist interleukin-15 (IL-15) complex

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ETBX-051
Description: Ad5 \[E1-, E2b-\]-Brachyury

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ETBX-061
Description: Ad5 \[E1-, E2b-\]-MUC1

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GI-6301
Description: Heat-killed S. cerevisiae yeast expressing the human Brachyury (hBrachyury) oncoprotein

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: haNK
Description: NK-92 \[CD16.158V, ER IL-2\] (high-affinity activated Natural Killer cells)
Study: NCT02939599

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QCC374
Description: 0.015mg and 0.06mg
Study: NCT01612377

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone-Dipyridamole
Description: Oral, QD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Oral QD Prednisone 5mg
Study: NCT03338868

Intervention type: OTHER
Intervention: Musculoskeletal pain intensity
Description: evaluated with Visual Analog Scale

Intervention type: OTHER
Intervention: Musculoskeletal pain intensity
Description: evaluated with Visual Analog Scale
Study: NCT02272946

Intervention type: DRUG
Group type: OTHER
Intervention: Canakinumab
Description: 150mg Canakinumab received subcutaneously

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 150mg Placebo received subcutaneously
Study: NCT01015755

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: combined therapy treatment
Description: mouth care
Study: NCT00720577

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simvastatin
Description: 40 Mg. tablet, 1 tablet daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Losartan
Description: 50 mg., tablets, 1 tablet once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone
Description: 30 mg, tablet, 1 tablet once daily
Study: NCT04532840

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cryotherapy (Gymna Cryoflow ICE-CT)
Description: Cryotherapy (also called cryoablation) method was produced by James Arnot in England in 1945 to reduce the size of cancerous cells based on the theory that cold blood cells destroy the cells. Campbell White of New York City used cryotherapy as the first dermatological indication in early-stage epithelioma patients in 1890. Later in 1907, Whitehouse described the use of this method in diferent diseases such as pigmented nevus and lupus. In addition, he has published a case series of skin cancers in different face regions.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercising, Positioning and splinting, Pressure Therapy and Massage
Description: Exercising, Positioning and splinting, Pressure Therapy and Massage

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercising, Positioning and splinting, Pressure Therapy and Massage
Description: Exercising, Positioning and splinting, Pressure Therapy and Massage
Study: NCT04794868

Intervention type: DIAGNOSTIC_TEST
Intervention: CCTA-derived high risk plaque characteristics
Description: Presence of CCTA-derived high risk plaque characteristics

Intervention type: DIAGNOSTIC_TEST
Intervention: CCTA-derived high risk plaque characteristics
Description: Presence of CCTA-derived high risk plaque characteristics

Intervention type: DIAGNOSTIC_TEST
Intervention: CFD-derived hemodynamic parameters
Description: CFD-derived hemodynamic parameters

Intervention type: DIAGNOSTIC_TEST
Intervention: CFD-derived hemodynamic parameters
Description: CFD-derived hemodynamic parameters
Study: NCT05807152

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RenalGuard device
Description: Patients will be given an intravenous loading dose of 40 mg of furosemide and continuous infusion of furosemide based on baseline eGFR. An additional bolus of 40 mg of furosemide will be administered and the infusion rate increased according to the same protocol of the control group (Figure 1). The venous peripheral cannula will be connected with the extracorporeal circuit of the RenalGuard System (PLC Medical Systems Inc., MA) for fluid infusion. The RenalGuard System is capable of delivering sterile replacement solution to a patient in an amount matched, or higher or lower, to the volume of urine produced by the patient. Thus, in the RenalGuard group, estimated daily targeted negative fluid balance will be utilized to define, for each patient, hourly negative fluid balance to be set in the RenalGuard system display.
Study: NCT00178971

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: adjunctive treatment with buspirone
Description: buspirone 15-30 mg qd

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study: NCT01612377

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prednisone
Description: Oral, QD prednisone 7.5mg
Study: NCT01390480

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cholecalciferol
Description: weekly dose (based on 70 IU/kg bodyweight/day) orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol
Description: weekly dose (based on 70 IU/kg bodyweight/day) orally
Study: NCT00091026

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: Given IV
Study: NCT01880190

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ringer's Lactate

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: HES 130/0.4 and Ringer's Lactate
Study: NCT02626936

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dual-hormone closed-loop
Description: Interventions will be undertaken one to 5 days after sensor insertion. Subjects will be admitted at the research center at 7:00 am. Subject's pump will be substituted with the study pump and an additional pump containing glucagon will be installed. At 7:00, CLS will be initiated. At 9:00, a standardized breakfast (75g CHO) will be served. Study subjects will consume the same meal on the two intervention days. During the intervention, patients will be allowed to do sedentary activities. Patients will allowed to consume caffeine during the intervention, but will have to replicate their caffeine consumption on both interventions.The intervention day will end at 13:00.
Study: NCT00091026

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride
Description: Given orally
Study: NCT03448900

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multicomponent intervention
Description: Motivational interview (50 minutes), on-line self-help material, support e-mail, group therapy, and second motivational interview (20 minutes)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief advice
Description: Brief advice (5-10minutes) and a self-help pamphlet
Study: NCT03396978

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GnRHag
Description: Ovarian Hormone Suppression - the purpose of the intervention is not to study the drug, but the impact of the loss of ovarian hormones.
Study: NCT03775590

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Water
Description: To evaluate using water in the treatment of atopic dermatitis

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bleach
Description: To evaluate using water + dilute bleach in the treatment of atopic dermatitis

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Acetic acid
Description: To evaluate using water + vinegar in the treatment of atopic dermatitis
Study: NCT04286464

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT01579552

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: survey, questionaire
Description: The intervention components (mailed tailored print materials followed by telephone-delivered Brief MI). Following enrollment into the study and completion of the informed consent form and baseline survey, participants will be randomized to the active intervention group or the attention control group. The data that will be used in the analysis will come from the baseline survey, medical records of breast imaging studies, and a 12-month follow-up questionnaire.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: survey, questionaire
Description: The intervention components (mailed tailored print materials followed by telephone-delivered Brief MI). Following enrollment into the study and completion of the informed consent form and baseline survey, participants will be randomized to the active intervention group or the attention control group. The data that will be used in the analysis will come from the baseline survey, medical records of breast imaging studies, and a 12-month follow-up questionnaire.
Study: NCT04643795

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MGL-3196
Description: Once daily oral dose for 6 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MGL-3196
Description: Once daily oral dose for 6 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MGL-3196
Description: Once daily oral dose for 6 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MGL-3196
Description: Once daily oral dose for 6 days
Study: NCT01653002

Intervention type: OTHER
Intervention: No intervention
Study: NCT00889395

Intervention type: BEHAVIORAL
Group type: NO_INTERVENTION
Intervention: MISC training for primary caregivers
Description: Caregivers of children in the intervention arm will undergo a year long training in MISC
Study: NCT03304327

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness and Yoga Training
Description: Centering and Breathing- Practice begins by turning attention to the breath to help participants make the transition from the busy, doing, outward focus of daily life into the mindful, balanced, internal focus central to yoga practice.~Practices:Breath awareness, the relaxed abdominal breath. Posture Practice-Warm up with the range-of-motion sequence to take the major joints of the body through their full range of motion.This is done lying down with the head on the floor; the head can be supported by a small, folded towel if desired.~Practices: Knee-to-chest sequence, Arms and Shoulders, Gentle Spinal Twist, Apanasana.~Standing Poses for Strength and Balance, to enhance function and confidence. Practices: Mountain Pose, Flying Crane Sequence, Tree Pose, Warrior 2 and Side Angle.~Relaxation- Practice concludes with guided relaxation to quiet the mind and calm the body.~Practices: Seated Mountain Pose, even breath, extended exhalation,Yoga Nidra.
Study: NCT04915326

Intervention type: PROCEDURE
Intervention: rectal resection
Description: every patients will undergo to the appropriate rectal resection

Intervention type: PROCEDURE
Intervention: rectal resection
Description: every patients will undergo to the appropriate rectal resection
Study: NCT03024840

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: Sevoflurane: 1%\~2%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Propofol: 9-15 mg/kg/h
Study: NCT04929418

Intervention type: OTHER
Group type: OTHER
Intervention: 10 km continuous running
Description: Trial participants will perform a 10 km continuous running exercise

Intervention type: OTHER
Group type: OTHER
Intervention: 10 km continuous running
Description: Trial participants will perform a 10 km continuous running exercise

Intervention type: OTHER
Group type: OTHER
Intervention: 1.5 km continuous swimming
Description: Trial participants will perform a 1.5 km continuous swimming exercise.

Intervention type: OTHER
Group type: OTHER
Intervention: 1.5 km continuous swimming
Description: Trial participants will perform a 1.5 km continuous swimming exercise.
Study: NCT04568018

Intervention type: DRUG
Intervention: Surfactant
Description: Inhalation of surfactant emulsion at 150 mg

Intervention type: DRUG
Intervention: Surfactant
Description: Inhalation of surfactant emulsion at 150 mg

Intervention type: DRUG
Intervention: Surfactant
Description: Inhalation of surfactant emulsion at 150 mg

Intervention type: DRUG
Intervention: Surfactant
Description: Inhalation of surfactant emulsion at 150 mg
Study: NCT03920878

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aflibercept injected Pre- and Post-operatively
Description: Three injections of aflibercept before cataract surgery, and aflibercept injections after surgery within 14-21 days of the day of surgery (number of injections depends on clinical exam findings, visual acuity and retinal thickness).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aflibercept injected intraoperatively
Description: Three injections of aflibercept before surgery and one injection of aflibercept during the course of the surgery by cataract surgeon.
Study: NCT00270998

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Therapy
Description: Pelvic muscle training and exercises

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intravaginal Pessary
Description: Intravaginal pessary

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pessary combined with behavioral therapy
Description: Intravaginal pessary and behavioral therapy
Study: NCT02751021

Intervention type: OTHER
Group type: OTHER
Intervention: pacemaker diagnostic algorithm
Description: evaluation of the respiratory disturbance index by measurement of transthoracic impedance variation, to detect sleep apnea

Intervention type: OTHER
Group type: OTHER
Intervention: Attended cardiorespiratory sleep study
Description: sleep study with portable monitor resulting in the apnea hypopnea index, to confirm sleep apnea diagnosis
Study: NCT04655209

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: apply a-tDCS on the ipsilesional M1 followed by MT (M1-Seq)
Description: The participants in the M1-Seq group will first receive a-tDCS over ipsi-lesional M1 without any active arm practice for 20 minutes. For the next 20 minutes, the participants will start the MT, while the electrodes will be remained on the scalp with the stimulator off (sham tDCS condition). Then the electrodes will be removed, and the participants will receive additional 20 minutes of MT without tDCS followed by 30 minutes of functional task practice.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: apply a-tDCS on the ipsilesional PMC followed by MT (PMC-Seq)
Description: The procedures for the PMC-Seq group will be the same as the M1-Seq, except that a-tDCS will be applied on ipsilesional PMC but not M1.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: MT only with sham tDCS (MT)
Description: For the MT group, the procedure will be the same as the other groups except that sham tDCS will be used for the first 40 minutes.
Study: NCT04026971

Intervention type: PROCEDURE
Group type: OTHER
Intervention: This study is a randomized controlled study aiming to evaluate the effect of phone application supported nutrition education on weight loss according to standard education.
Description: This study is a randomized controlled study aiming to evaluate the effect of phone application supported nutrition education on weight loss according to standard education.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: This study is a randomized controlled study aiming to evaluate the effect of phone application supported nutrition education on weight loss according to standard education.
Description: This study is a randomized controlled study aiming to evaluate the effect of phone application supported nutrition education on weight loss according to standard education.
Study: NCT04965168

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: phacoemulsification of the lens
Description: all patients underwent phacoemulsification and IOL implantation for immature cataract extraction

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: phacoemulsification of the lens
Description: all patients underwent phacoemulsification and IOL implantation for immature cataract extraction

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: phacoemulsification of the lens
Description: all patients underwent phacoemulsification and IOL implantation for immature cataract extraction

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: phacoemulsification of the lens
Description: all patients underwent phacoemulsification and IOL implantation for immature cataract extraction
Study: NCT01767012

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Polylens EC-HY10-PAL (coated)
Description: hydrophobic acrylic IOL with modified surface properties (Heparin-coating)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Polylens EC-Y10-PAL (uncoated)
Study: NCT00156910

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin Type A
Description: Two treatment sessions in the double-blind phase and three treatment sessions in the open-label extension phase. Total minimum dose is 155 U with 31 fixed-site, fixed dose injections across seven specific head/neck muscle areas with the total maximum dose of 195 U with 39 head/neck injections.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (saline)
Description: Two treatment sessions in the double-blind phase. Total minimum dose in 155 U with 31 fixed-site, fixed dose injections across seven specific head/neck muscle areas and the total maximum dose is 195 U with 39 head/neck injections.
Study: NCT02626936

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dual-hormone closed-loop
Description: Interventions will be undertaken one to 5 days after sensor insertion. Subjects will be admitted at the research center at 7:00 am. Subject's pump will be substituted with the study pump and an additional pump containing glucagon will be installed. At 7:00, CLS will be initiated. At 9:00, a standardized breakfast (75g CHO) will be served. Study subjects will consume the same meal on the two intervention days. During the intervention, patients will be allowed to do sedentary activities. Patients will allowed to consume caffeine during the intervention, but will have to replicate their caffeine consumption on both interventions.The intervention day will end at 13:00.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Description: Participant's usual fast-acting insulin analog will be used: Lispro (Humalog), Aspart (NovoRapid) or Glulisine (Apidra)
Study: NCT01896739

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Eutravac

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Eutravac

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Eutravac

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Eutravac
Study: NCT03419936

Intervention type: DIAGNOSTIC_TEST
Intervention: Endoscopic biopsy
Description: 1. Pre-operation (initial diagnosis) Assessment atrophy and metaplasia in stomach, Check Helicobacter pylori~2. Post-subtotal gastrectomy (After 6 months) Assess the distribution of helicobacter pylori after subtotal gastrectomy.~3. Post-subtotal gastrectomy (After 12 months) Assess the distribution of helicobacter pylori after subtotal gastrectomy.~4. Post-subtotal gastrectomy (After 24 months) Assess the distribution of helicobacter pylori after subtotal gastrectomy.
Study: NCT00516412

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: everolimus
Description: Patients receive oral everolimus once daily on days 1-28. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: molecular response by PCR
Description: Bone marrow and peripheral blood samples are collected periodically and analyzed for molecular response by PCR. Molecular studies are also performed on DNA level formalin-fixed paraffin-embedded tissue
Study: NCT04564066

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: efgartigimod IV
Description: intravenous infusions of efgartigimod

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: efgartigimod PH20 SC
Description: subcutaneous injections of efgartigimod PH20 SC